PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
32
investment:
Withheld
Morgan Goodwin is a UK-based company that pioneers the Combined Trading Platform (CTP) category, offering a comprehensive online platform for small businesses engaged in physical goods trading, along with specialized software development services, and a broad-spectrum business consultancy approach aimed at enhancing growth, efficiency, and technological advancement.
days to go:
Stretch
investment:
£788,519
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Doqit offers a solution for managing life admin tasks, helping you organize important information, set action dates, and receive timely reminders, ultimately streamlining tasks like insurance renewals and warranties to reduce unnecessary expenses and simplify your life. It provides secure storage and easy access for vital information, transitioning from chaos to simplicity.
Security is also a priority for Doqit. The platform ensures that your sensitive information is stored securely, giving you peace of mind knowing that you can access your important documents and data whenever you need them, all within a few clicks.
days to go:
Extended
investment:
£87,500
UTU is a company dedicated to building the trust infrastructure for the evolving web 3.0. They aim to facilitate safer and more reliable interactions between users and platforms by utilizing a decentralized reputation and reviews protocol. This protocol involves a non-tradable reputation token (UTT) that users can stake to endorse others, leading to positive outcomes. UTU's focus initially lies in Web3 and DeFi apps, where they provide AI-powered tools to curate trust signals and help users engage confidently in various online activities. They offer a range of products, including the UTU Trust Token, Browser Extension, and Trust API/SDK, all aimed at enhancing trust and security in digital interactions.
days to go:
Extended
investment:
£150,000
Wi-Fi Securities Limited is a cyber security company that aims to revolutionise the security of public access Wi-Fi. To realise this vision, the company is developing a unique patent-protected system called SpriteGuard™ which will protect you and your data from hackers by stopping you connecting to fake hotspots. The system is targeted towards the $550 bn worldwide hospitality industry and has the ability to expand to other large global markets like city-wide free Wi-Fi, airports and coffee shops. Moreover, Wi-Fi Securities Limited has a highly experienced Wi-Fi Securities management board that has a track record of delivering multi-million-pound projects from concept to successful commercial deployment.
days to go:
Extended
investment:
£1,014,708
Medic Bleep is a simple, secure and innovative patient-focused solution to communication challenges that healthcare professionals and the wider team in the UK National Health Service (NHS) face while going about their everyday work. It is saving each nurse & each junior doctor an estimated 48 minutes per shift. This coincides with the UK's Department of Health calling for a ban on pagers. If implemented across the NHS, it could free up the time to care for an estimated 11,000 nurses. To ensure data privacy and safety, the company allows communication to occur via the app. As a result of these safeguards and its user-friendly portal, the company's app has been downloaded 16,000 times by UK doctors and nurses. With the funds raised, the company will aim to solve looming technology gaps for over 30% of the NHS in the next 3 years and expand globally.
days to go:
Expired
investment:
£814,600
Your Cloud | Your WayEveryCloud Computing has developed a white label platform for resellers to become leading cloud providers. Sold through the reseller channel, EveryCloud offer three cloud packages that can be tailored to fit a customer, through subscription based pricing:Managed BackupHosted ServersCloud DriveResellers wanting to offer cloud services need to build new platforms and design new services, which have the appropriate support, billing processes and service delivery to support their customers’ demands. As businesses look to source a variety of different cloud services, increasingly from one trusted supplier, it can be hard for resellers, especially those on the smaller side, to have the funds to develop such infrastructure. Through EveryClouds products and services, resellers can deliver innovative storage and data management solutions that satisfy their most demanding customers. Cloud computing will reduce hardware investment, minimise maintenance costs and allow the customer to focus on their own business.The EveryCloud PortalThe web portal enables its customers to purchase online services and software from a range of vendors including EveryCloud. The portal is also used to manage the deployment of these purchases to the customers’ users. This includes adding & removing users, upgrading between products and adding & removing products. Uniquely, this portal can be white-labelled to allow resellers to brand it as their own, allowing them to operate to their customers as it they were direct suppliers of Cloud services. Amongst the services that can be purchased from the EveryCloud portal are a number of EveryCloud products including; EveryCloud Virtual desktop, EveryCloud e-mail, EveryCloud Virtual Servers and a range of data protection solutions. The OpportunityThe reseller channel represents 60% of all IT spend, which means that £36bn in the UK alone can be attributed to the reseller channel. There are tens of thousands of IT resellers in the UK, with a turnover ranging from hundreds of millions of pounds down to tens of thousands. This is EveryCloud’s target market.It appears that resellers are struggling to adapt to selling Cloud services in the new paradigm of monthly subscriptions versus single one-off purchases of hardware, software and licenses. In addition, the directors believe that providers of Cloud services have failed to offer resellers what they need to be able to successfully sell these services.EveryCloud is sold as a product to the reseller who will then sell onto their client. There is no direct sales channel from EveryCloud. The EveryCloud Platform will allow resellers to offer cloud solutions built on the latest technology, without the capital investment currently needed to develop their own system. Following previous funding rounds through Acceleris Capital, shareholders are supporting this development funding round of £200,000. The company are now prepared to offer the remaining amount of the funding round to Investing Zone investors on the same terms as the original shareholders at a minimum investment of £1000. Why is EveryCloud different?Enables end users to buy what they want/ need in a single, flexible, variable monthly transaction. The current alternative is similar to buying groceries one item at a time, with a different transaction for each item.EveryCloud provides its resellers with generous profit margins through the provision of:• The ability to offer multiple services through a single transaction, branded in their own livery, as if they were a Cloud provider in their own right; • The ability to provision and de-provision users quickly and efficiently; • Transparent automated billing so customers only see the reseller as a sole supplier; and • Training in the sales process and comprehensive support in customer enablement.Initially targeted at companies and resellers of a smaller size, EveryCloud has the capability to grow as the demand for the service increases. You need to be registered as an investor to see thisJoin Now
days to go:
Expired
investment:
£149,809
